title: Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues.
abstract: To assess the role of insulin-like growth factors (IGFs) in growth and transformation of normal (myometrium) and tumorous smooth muscle cell (SMC) tissues, in situ hybridization (ISH) analysis for insulin-like growth factor I and II (IGF-I and IGF-II) mRNAs was combined with detection of IGF peptides, their receptors and IGF binding protein-3 (IGFBP-3). mRNAs for both IGFs were detected in smooth muscle cells in normal, benign and malignant SMC tissues, together with the IGF peptides, both IGF receptors and IGFBP-3. This suggests an autocrine role for both IGFs. Leiomyomas had higher IGF-I peptide levels and higher levels of type I IGF receptors than myometrium, supporting the idea that IGFs play a role in the growth and transformation of these tumours. Low-grade leiomyosarcomas contained more IGF-II mRNAs than myometrium and leiomyoma, fewer type II IGF/mannose 6-phosphate receptors and less IGFBP-3 than myometrium and, in addition, fewer IGF-I mRNAs and type I IGF receptors than leiomyoma. Intermediate- and high-grade leiomyosarcomas had intermediate levels of IGF-II mRNAs and peptide, ranging between those in myometrium and low-grade leiomyosarcomas. Thus, growth and transformation of leiomyosarcomas may be regulated by IGF-II, although more markedly in low-grade than in high-grade leiomyosarcomas. In conclusion, the various categories of SMC tissues are associated with a distinct expression pattern of the IGF system. This suggests that each category of SMC tumours arises as a distinct entity and that there is no progression of transformation in these tissues.
authors.affiliation: Department of Functional Morphology, Veterinary Faculty Utrecht University, The Netherlands.
authors.forename: L T
authors.initials: LT
authors.lastname: Van der Ven
authors.forename: P J
authors.initials: PJ
authors.lastname: Roholl
authors.forename: T
authors.initials: T
authors.lastname: Gloudemans
authors.forename: S C
authors.initials: SC
authors.lastname: Van Buul-Offers
authors.forename: M J
authors.initials: MJ
authors.lastname: Welters
authors.forename: B A
authors.initials: BA
authors.lastname: Bladergroen
authors.forename: J A
authors.initials: JA
authors.lastname: Faber
authors.forename: J S
authors.initials: JS
authors.lastname: Sussenbach
authors.forename: W
authors.initials: W
authors.lastname: Den Otter
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000032:analysis*; D007334:Insulin-Like Growth Factor I / Q000032:analysis* / Q000235:genetics; D007335:Insulin-Like Growth Factor II / Q000032:analysis* / Q000235:genetics; D007889:Leiomyoma / Q000737:chemistry*; D007890:Leiomyosarcoma / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000737:chemistry*; D012333:RNA, Messenger / Q000032:analysis; D017526:Receptor, IGF Type 1 / Q000032:analysis*; D017527:Receptor, IGF Type 2 / Q000032:analysis*
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D012333:RNA, Messenger; D017527:Receptor, IGF Type 2; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D017526:Receptor, IGF Type 1